A new role of vemurafenib as a neoadjuvant treatment of axillary and brain melanoma metastases.
Vemurafenib is approved by the FDA for the management of unresectable or metastatic melanoma. However, its role as a neoadjuvant therapy has not been determined. We present the first documented case in which vemurafenib induced complete tumor necrosis of both lymph node and brain metastases within one month or less, an outcome that indicated that the patient was a good candidate for excisional surgery.
Department of General and Vascular Surgery, Barzilai Medical Center, Hahistadrut Street 2, 78278 Ashkelon, Israel.
Idit
I
Melnik
Center for Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, P.O. Box 12000, 91120 Jerusalem, Israel.
Michal
M
Lotem
Department of General and Vascular Surgery, Barzilai Medical Center, Hahistadrut Street 2, 78278 Ashkelon, Israel.
Boris
B
Yoffe